David Dai
Stock Analyst at UBS
(3.47)
# 2,290
Out of 5,070 analysts
110
Total ratings
48.8%
Success rate
5.9%
Average return
Main Sectors:
Stocks Rated by David Dai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CATX Perspective Therapeutics | Reiterated: Buy | $8 | $2.30 | +247.83% | 4 | Oct 2, 2026 | |
| SMMT Summit Therapeutics | Reiterated: Buy | $33 | $16.09 | +105.10% | 11 | Sep 28, 2026 | |
| NBTX Nanobiotix | Reiterated: Hold | $30 | $24.14 | +24.28% | 6 | Sep 25, 2026 | |
| BNTX BioNTech SE | Reiterated: Buy | $135 | $91.17 | +48.08% | 3 | Sep 16, 2026 | |
| ENGN enGene Therapeutics | Rated: Hold | $2 | $1.67 | +19.76% | 5 | Sep 16, 2026 | |
| CGON CG Oncology | Rated: Buy | $90 | $61.93 | +45.33% | 5 | Aug 21, 2026 | |
| KURA Kura Oncology | Rated: Buy | $15 | $9.98 | +50.30% | 8 | Aug 21, 2026 | |
| SNDX Syndax Pharmaceuticals | Rated: Buy | $37 → $33 | $13.25 | +149.06% | 5 | Aug 21, 2026 | |
| IOVA Iovance Biotherapeutics | Rated: Hold | $4 → $7 | $14.86 | -52.89% | 4 | Aug 20, 2026 | |
| CGEM Cullinan Therapeutics | Reiterated: Buy | $24 → $27 | $14.83 | +82.06% | 8 | Aug 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $128 | $113.46 | +12.82% | 3 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $23 → $31 | $26.10 | +18.77% | 6 | Jul 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $45 | $30.29 | +48.56% | 2 | Jun 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $69 → $15 | $17.20 | -12.79% | 2 | Apr 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $31.00 | $14.61 | +112.26% | 13 | Apr 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $1.5 | $0.4999 | +200.06% | 2 | Apr 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $40 → $34 | $242.08 | -85.96% | 3 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $546 | $514.65 | +6.09% | 1 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $112 | $156.51 | -28.44% | 1 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $50 | $35.36 | +41.40% | 3 | Oct 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | ¥2,690 | ¥7,498 | n/a | 6 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | ¥34,600 | ¥10,295 | n/a | 1 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | ¥3,900 | ¥3,971 | n/a | 1 | Jan 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $5 | $6.42 | n/a | 1 | Sep 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $40 → $5 | $3.49 | n/a | 2 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $40 | $1.74 | n/a | 1 | May 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $54 | $24.94 | n/a | 2 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $28 | $4.52 | n/a | 1 | Mar 30, 2022 |
Perspective Therapeutics
Oct 2, 2026
Reiterated: Buy
Price Target: $8
Current: $2.30
Upside: +247.83%
Summit Therapeutics
Sep 28, 2026
Reiterated: Buy
Price Target: $33
Current: $16.09
Upside: +105.10%
Nanobiotix
Sep 25, 2026
Reiterated: Hold
Price Target: $30
Current: $24.14
Upside: +24.28%
BioNTech SE
Sep 16, 2026
Reiterated: Buy
Price Target: $135
Current: $91.17
Upside: +48.08%
enGene Therapeutics
Sep 16, 2026
Rated: Hold
Price Target: $2
Current: $1.67
Upside: +19.76%
CG Oncology
Aug 21, 2026
Rated: Buy
Price Target: $90
Current: $61.93
Upside: +45.33%
Kura Oncology
Aug 21, 2026
Rated: Buy
Price Target: $15
Current: $9.98
Upside: +50.30%
Syndax Pharmaceuticals
Aug 21, 2026
Rated: Buy
Price Target: $37 → $33
Current: $13.25
Upside: +149.06%
Iovance Biotherapeutics
Aug 20, 2026
Rated: Hold
Price Target: $4 → $7
Current: $14.86
Upside: -52.89%
Cullinan Therapeutics
Aug 17, 2026
Reiterated: Buy
Price Target: $24 → $27
Current: $14.83
Upside: +82.06%
Aug 5, 2026
Reiterated: Buy
Price Target: $128
Current: $113.46
Upside: +12.82%
Jul 22, 2026
Rated: Buy
Price Target: $23 → $31
Current: $26.10
Upside: +18.77%
Jun 16, 2026
Reiterated: Buy
Price Target: $45
Current: $30.29
Upside: +48.56%
Apr 15, 2026
Downgraded: Hold
Price Target: $69 → $15
Current: $17.20
Upside: -12.79%
Apr 8, 2026
Reiterated: Buy
Price Target: $31.00
Current: $14.61
Upside: +112.26%
Apr 2, 2026
Reiterated: Hold
Price Target: $1.5
Current: $0.4999
Upside: +200.06%
Jan 7, 2026
Downgraded: Hold
Price Target: $40 → $34
Current: $242.08
Upside: -85.96%
Nov 7, 2025
Reiterated: Buy
Price Target: $546
Current: $514.65
Upside: +6.09%
Oct 31, 2025
Reiterated: Hold
Price Target: $112
Current: $156.51
Upside: -28.44%
Oct 24, 2025
Reiterated: Buy
Price Target: $50
Current: $35.36
Upside: +41.40%
Apr 2, 2025
Reiterated: Hold
Price Target: ¥2,690
Current: ¥7,498
Upside: n/a
Feb 26, 2025
Reiterated: Buy
Price Target: ¥34,600
Current: ¥10,295
Upside: n/a
Jan 15, 2025
Initiated Coverage: Buy
Price Target: ¥3,900
Current: ¥3,971
Upside: n/a
Sep 29, 2022
Initiated Coverage: Buy
Price Target: $5
Current: $6.42
Upside: n/a
Jul 18, 2022
Downgraded: Hold
Price Target: $40 → $5
Current: $3.49
Upside: n/a
May 16, 2022
Reiterated: Buy
Price Target: $40
Current: $1.74
Upside: n/a
May 9, 2022
Reiterated: Buy
Price Target: $54
Current: $24.94
Upside: n/a
Mar 30, 2022
Initiated Coverage: Buy
Price Target: $28
Current: $4.52
Upside: n/a